Passage Bio, Inc. - Passage Bio Announces Positive Interim …
https://investors.passagebio.com/investors-and-news/press-releases-and-statements/news-details/2022/Passage-Bio-Announces-Positive-Interim-Clinical-Data-from-First-Six-Patients-with-GM1-Gangliosidosis-in-Imagine-1-Study/default.aspx
WEBPHILADELPHIA, Dec. 14, 2022 (GLOBE NEWSWIRE) -- Passage Bio, Inc. (Nasdaq: PASG), a clinical-stage genetic medicines company focused on developing transformative therapies for central nervous system (CNS) disorders, today announced new interim safety, biomarker, and clinical development results from cohorts 1-3 in the Imagine-1 clinical study.
DA: 89 PA: 83 MOZ Rank: 83